Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of “Hold” by Analysts

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has received an average recommendation of “Hold” from the twenty-one brokerages that are currently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell recommendation, nine have assigned a hold recommendation and nine have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $18.00.

A number of equities analysts recently issued reports on the stock. Bank of America dropped their price target on shares of Intellia Therapeutics from $36.00 to $30.00 and set a “buy” rating on the stock in a research note on Monday, October 27th. Wells Fargo & Company reduced their price target on shares of Intellia Therapeutics from $17.00 to $12.00 and set an “equal weight” rating for the company in a research report on Friday, November 7th. Guggenheim cut Intellia Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, October 27th. HC Wainwright increased their target price on Intellia Therapeutics from $15.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, January 28th. Finally, Truist Financial restated a “buy” rating and issued a $14.00 price target (down previously from $25.00) on shares of Intellia Therapeutics in a research note on Monday, November 10th.

Insider Transactions at Intellia Therapeutics

In related news, CEO John M. Leonard sold 34,146 shares of Intellia Therapeutics stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $314,484.66. Following the completion of the sale, the chief executive officer owned 1,013,339 shares of the company’s stock, valued at $9,332,852.19. The trade was a 3.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP James Basta sold 10,397 shares of the stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $95,756.37. Following the completion of the transaction, the executive vice president directly owned 101,528 shares in the company, valued at approximately $935,072.88. This represents a 9.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 53,051 shares of company stock worth $488,600 in the last ninety days. Insiders own 3.10% of the company’s stock.

Institutional Trading of Intellia Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd bought a new position in Intellia Therapeutics in the third quarter worth approximately $30,000. Blue Bell Private Wealth Management LLC purchased a new stake in shares of Intellia Therapeutics in the 3rd quarter worth $30,000. Advisory Services Network LLC bought a new position in Intellia Therapeutics in the 3rd quarter worth $33,000. Headlands Technologies LLC purchased a new position in Intellia Therapeutics during the second quarter valued at $26,000. Finally, Comerica Bank grew its holdings in Intellia Therapeutics by 45.8% during the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after purchasing an additional 901 shares during the period. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Stock Up 10.7%

NTLA stock opened at $12.28 on Monday. The business has a 50 day moving average of $10.82 and a 200 day moving average of $12.96. The firm has a market cap of $1.42 billion, a PE ratio of -2.88 and a beta of 2.10. Intellia Therapeutics has a twelve month low of $5.90 and a twelve month high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, November 6th. The company reported ($0.92) EPS for the quarter, topping the consensus estimate of ($1.02) by $0.10. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.The business had revenue of $13.78 million for the quarter, compared to the consensus estimate of $14.12 million. During the same period in the previous year, the company posted ($1.34) earnings per share. The company’s revenue for the quarter was up 51.6% compared to the same quarter last year. On average, research analysts expect that Intellia Therapeutics will post -5.07 earnings per share for the current fiscal year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.